Obesity and Hypogonadism




The relationship between obesity and hypogonadism is complicated. The relationship is bidirectional and there are numerous causative and correlative factors on both sides of the equation. Obesity is increasing in prevalence in epidemic proportions. Likewise, we are beginning to see the rapid increase in the incidence of male hypogonadism. It is only recently that we are learning the ways in which these 2 conditions exacerbate each other, and we are only beginning to understand how by treating one of these conditions, we can help to treat the other as well.




It is only recently that we are learning the ways in which these 2 conditions exacerbate each other.




It is only recently that we are learning the ways in which these 2 conditions exacerbate each other.




Clearly the relationship between hypogonadism and obesity is complicated and questions remain surrounding the degree of correlation and causality between the 2 conditions. What is known is that these 2 conditions have been discovered to coexist with frequency and treatment of one of these conditions may confer potential benefits on the other. There are numerous speculations as to the physiology behind these mechanisms.




Over the years, we have also come to understand that the function of adipose tissue is largely determined by its location. Visceral adipose tissue secretes its endocrine hormones directly into the portal system, whereas subcutaneous tissue secretes into systemic circulation. Hence, visceral adiposity has a greater effect on hepatic metabolic function. Expression of IL-6 is higher in visceral adipose tissue, whereas expression of leptin is higher in subcutaneous tissue. Finally, these different types of tissue respond differently to afferent signals, largely because visceral tissue has higher levels of glucocorticoid and androgen receptors. Most interesting, however, is that visceral fat is associated with increased metabolic risk and mortality, whereas subcutaneous fat expansion actually improves insulin sensitivity, and reduces the risk of type 2 diabetes.










References



  1. 1. Ogden C., Carroll M., and Kit B.: Prevalence of childhood and adult obesity in the United States, 2011-2012. JAMA 2014; 311: pp. 806-814

  2. 2. World Health Organization : Obesity and overweight. WHO fact sheet. Geneva (Switzerland): World Health Organization, 2015.

  3. 3. Jensen M.D., Ryan D.H., Apovian C.M., et al: Guideline for the management of overweight and obesity for adults. J Am Coll Cardiol 2014; 63: pp. 2985-3023

  4. 4. Shrager B., Jibara G.A., Tabrizian P., et al: Resection of nonalcoholic steatohepatitis-associated hepatocellular carcinoma: a Western experience. Int J Surg Oncol 2012; 2012: pp. 915128

  5. 5. Lamm S.: Fighting fat. Ann Arbor (MI): Spry Publishing LLC, 2015.

  6. 6. Mulligan T., Frick M.F., Zuraw Q.C., et al: Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006; 60: pp. 762-769

  7. 7. Corona G., Rastrelli G., Monami M., et al: Body weight loss reverts obesity–associated hypogonadotropic hypogonadism: a systematic review and meta-analysis. Eur J Endocrinol 2013; 168: pp. 829-843

  8. 8. Lunenfeld B., Mskhalaya G., Zitzmann M., et al: Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male 2015; 18: pp. 5-15

  9. 9. Kapoor D., Malkin C.J., Channer K.S., et al: Androgens, insulin resistance and vascular disease in men. Clin Endocrinol 2005; 63: pp. 239-250

  10. 10. Saad F., Haider A., Doros G., et al: Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring) 2013; 21: pp. 1975-1981

  11. 11. Yassin A., and Doros G.: testosterone therapy in hypogonadal men results and sustained in a clinically meaningful weight loss. Clin Obes 2013; 3: pp. 73-83

  12. 12. Kershaw E.E., and Flier J.S.: Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: pp. 2548-2556

  13. 13. Fain J.N., Madan A.K., Hiler M.L., et al: Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004; 145: pp. 2273-2282

  14. 14. Zhang F., Basinski M.B., Beals J.M., et al: Crystal structure of the obese protein leptin-E100. Nature 1997; 387: pp. 206-209

  15. 15. Ramíreza S., and Clareta Volume M.: Hypothalamic ER stress: a bridge between leptin resistance and obesity. FEBS Lett 2015; 589: pp. 1678-1687

  16. 16. Fernandez-Real J.M., and Ricart W.: Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003; 24: pp. 278-301

  17. 17. López-Jaramillo P., Gómez-Arbeláez D., López-López J., et al: The role of leptin/adiponectin ratio in metabolic syndrome and diabetes. Horm Mol Biol Clin Investig 2014; 18: pp. 37-45

  18. 18. Friedman J.M., and Halaas J.L.: Leptin and the regulation of body weight in mammals. Nature 1998; 395: pp. 763-770

  19. 19. Moreno-Eutimio M.A., and Acosta-Altamirano G.: Immunometabolism of exercise and sedentary lifestyle. Cir Cir 2014; 82: pp. 344-351

  20. 20. Balsan G.A., Vieira J.L., Oliveira A.M., et al: Relationship between adiponectin, obesity and insulin resistance. Rev Assoc Med Bras 2015; 61: pp. 72-80

  21. 21. ORourke R.W., Metcalf M.D., White A.E., et al: Depot-specific differences in inflammatory mediators and a role for NK cells and IFN-gamma in inflammation in human adipose tissue. Int J Obes (Lond) 2009; 33: pp. 978-990

  22. 22. Pischon T., Boeing H., Hoffmann K., et al: General and abdominal adiposity and risk of death in Europe. N Engl J Med 2008; 359: pp. 2105-2120

  23. 23. Misra A., Garg A., Abate N., et al: Relationship of anterior and posterior subcutaneous abdominal fat to insulin sensitivity in nondiabetic men. Obes Res 1997; 5: pp. 93-99

  24. 24. Mooradian A.D., Morley J.E., and Korenman S.G.: Biological actions of androgens. Endocr Rev 1987; 8: pp. 1-28

  25. 25. Morales A.B.J., Gooren L.J., Guay A.T., et al: Endocrine aspects of mens sexual dysfunction. In Lue T.F., Basson R., Rosen R., (eds): Sexual medicine, sexual dysfunctions in men and women, 2nd international consultation on sexual dysfunctions. Paris (France): Paris Health Publications, 2004. pp. 347-382

  26. 26. Pinzone J.: Principles and practice of endocrinology and metabolism. Philadelphia: Lippincott Williams & Wilkins, 2001.

  27. 27. Traish A.M., Abdullah B., and Yu G.: Androgen deficiency and mitochondrial dysfunction: implications for fatigue, muscle dysfunction, insulin resistance, diabetes, and cardiovascular disease. Horm Mol Biol Clin Investig 2011; 8: pp. 431-444

  28. 28. Rivas A., Mulkey Z., Lado-Abeal J., et al: Diagnosing and managing low serum testosterone. Proc (Bayl Univ Med Cent) 2014; 27: pp. 321-332

  29. 29. Allan C.A., and McLachlan R.I.: Androgens and obesity. Curr Opin Endocrinol Diabetes Obes 2010; 17: pp. 224-232

  30. 30. Bhasin S., Cunningham G.R., Hayes F.J., et al: Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: pp. 2536-2559

  31. 31. Grossmann M., Gianatti E.J., and Zajac J.D.: Testosterone and type 2 diabetes. Curr Opin Endocrinol Diabetes Obes 2010; 17: pp. 247-256

  32. 32. Licinio J., Caglayan S., Ozata M., et al: Phenotypic effects of leptin replacement on morbid obesity, diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl Acad Sci U S A 2004; 101: pp. 4531-4536

  33. 33. Belanger C., Luu-The V., Dupont P., et al: Adipose tissue intracrinology: potential importance of local androgen/estrogen metabolism in the regulation of adiposity. Horm Metab Res 2002; 34: pp. 737-745

  34. 34. Hammond G.L., and Bocchinfuso W.P.: Sex hormone-binding globulin: gene organization and structure/function analyses. Horm Res 1996; 45: pp. 197-201

  35. 35. Simó R., Sáez-López C., Barbosa-Desongles A., et al: Novel insights in SHBG regulation and clinical implications. Trends Endocrinol Metab 2015; 26: pp. 376-383

  36. 36. Lee W., Nagubadi S., Kryger M.H., et al: Epidemiology of obstructive sleep apnea: a population-based perspective. Expert Rev Respir Med 2008; 2: pp. 349-364

  37. 37. Pelusi C., and Pasquali R.: Testosterone levels in obese male patients with obstructive sleep apnea syndrome: relation to oxygen desaturation, body weight, fat distribution and the metabolic parameters. J Endocrinol Invest 2003; 26: pp. 493-498

  38. 38. Resta O., Foschino-Barbaro M.P., Legari G., et al: Sleep-related breathing disorders, loud snoring and excessive daytime sleepiness in obese subjects. Int J Obes Relat Metab Disord 2001; 25: pp. 669-675

  39. 39. Beccutia G., and Pannaina S.: Sleep and obesity. Curr Opin Clin Nutr Metab Care 2011; 14: pp. 402-412

  40. 40. Tsai E.C., Boko E.J., Leonetti D.L., et al: Low serum testosterone level as a predictor of increased visceral fat in Japanese-American men. Int J Obes Relat Metab Disord 2000; 24: pp. 485-491

  41. 41. Mauras N., Hayes V., Welch S., et al: Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab 1998; 83: pp. 1886-1892

  42. 42. Hoyes C.M., Yee B.J., Philllips C.L., et al: Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomized placebo-controlled trial. Eur J Endocrinol 2012; 167: pp. 531-541

  43. 43. Lee C.G., Boyko E.J., Nelson C.M., et al: Mortality risk in older men associated with changes in weight, lean mass, and fat mass. J Am Geriatr Soc 2011; 59: pp. 233-240

  44. 44. Ramirez M.E., McMurry M.P., Wiebje G.A., et al: Evidence for sex steroid inhibition of lipoprotein lipase in men: comparison of abdominal and femoral adipose tissue. Metabolism 1997; 46: pp. 179-185

  45. 45. Stellato R.K., Feldman H.A., Hamdy O., et al: Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000; 23: pp. 490-494

  46. 46. Jones T.H.: Testosterone association with erectile dysfunction, diabetes, and the metabolic syndrome. Eur Urol 2007; 6: pp. 847-857

  47. 47. Ng Tang Fui M., Dupuis P., and Grossmann M.: Lowered testosterone in male obesity: mechanisms, morbidity and management. Asian J Androl 2014; 16: pp. 223-231

  48. 48. Dixon J., Schachter L., and O’Brien P.: Sleep disturbance and obesity: changes following surgically induced weight loss. Arch Intern Med 2001; 161: pp. 102-106

  49. 49. Saad F., Aversa A., Isidori A.M., et al: Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev 2012; 8: pp. 131-143

  50. 50. Mårin P., Holmäng S., Gustafsson C., et al: Androgen treatment of abdominally obese men. Obes Res 1993; 1: pp. 245-251

  51. 51. Snyder P.J., Peachey H., Hannoush P., et al: Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. J Clin Endocrinol Metab 1999; 84: pp. 2647-2653

  52. 52. Kapoor D., Clarke S., Stanworth R., et al: The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2007; 156: pp. 595-602

  53. 53. Singh R., Artaza J.N., Taylor W.E., et al: Androgens stimulate myogenic differentiation and inhibit adipogenesis in C3H 10T1/2 pluripotent cells through an androgen receptor-mediated pathway. Endocrinology 2003; 144: pp. 5081-5088

  54. 54. Sattler F., Bhasin S., He J., et al: Testosterone threshold levels and lean tissue mass targets needed to enhance skeletal muscle strength and function: the HORMA trial. J Gerontol A Biol Sci Med Sci 2011; 66: pp. 122-129

Only gold members can continue reading. Log In or Register to continue

Related posts:

Default ThumbnailHypogonadism Default ThumbnailPhysiology of the Hypothalamic Pituitary Gonadal Axis in the Male Default ThumbnailHypogonadism Default ThumbnailTestosterone Deficiency and the Prostate Default ThumbnailTestosterone Therapy and Prostate Cancer Default ThumbnailTestosterone and Sexual Function

Stay updated, free articles. Join our Telegram channel
Tags:
Mar 3, 2017 | Posted by in UROLOGY | Comments Off on Obesity and Hypogonadism

Full access? Get Clinical Tree
Get Clinical Tree app for offline access